Stem cell therapy is an exciting area of research that holds tremendous potential for helping chronic pain patients reduce their pain. Rapid advances in this field of medicine are buoying doctors and patients hopes that the exciting therapy could change lives. Advances are being made nearly every day, and as scientists further understand the nature of these cells, even more uses for them are becoming known. If youve ever wondered about how stem cell therapy for pain could help you, these 15 questions delve into how this therapy works and who it could be used for.
Science has a strong interest in stem cells because of their renewing properties and the ability of these cells to develop into any type of tissue in the body of the organism. Researchers believe that they have the potential for immeasurable clinical uses in health. Research is advancing many stem cell based therapies for people who suffer from diseases such as:
Mayo Clinic explains how this therapy works:
Stem cell therapy, also known as regenerative medicine, promotes the reparative response of diseased, dysfunctional or injured tissue using stem cells or their derivativesResearchers grow stem cells in a lab. These stem cells are manipulated to specialize into specific types of cells, such as heart muscle cells, blood cells or nerve cells. The specialized cells can then be implanted into a person.
Stem cell therapy is actually a type of treatment within the larger umbrella of regenerative medicine. Our longer post on regenerative medicine discusses the types of treatments available, including stem cell therapy and platelet-rich plasma injections.
Stem cells are essentially blank canvases that can transform into any type of cell in the human body. Specialized cells like bone cells, liver cells, and heart cells begin as stem cells. The process of the cells transforming from blank slates into specialized cells is called differentiation.
Stem cell therapy is the process of injecting these cells into damaged areas of the body, such as arthritic knees or shoulders. The stem cells then differentiate into damaged tissue, helping to regenerate the entire area.
There are two different types of natural stem cells and one that is genetically reprogrammed within the laboratory. Embryonic stem cells are the most immature and are found within the early stages of a growing embryo, usually after it has been left to develop five to six days. After the egg and sperm have united, the fertilized egg divides and creates stem cells that differentiate into the specialized cells the body requires to function. Many techniques using stem cells for pain therapies no longer rely on these types of stem cells.
The second type of stem cell, found naturally in organisms, is adult stem cells. These are present in developed tissue, such as muscle, skin, bone, brain, and blood. Also called tissue stem cells, they can self-renew and generate one specialized cell type. Under normal circumstances these tissue stem cells, or adult stem cells, will generate the type of cells that make up the organ in which they reside. These cells are used by the body to divide and repair injured areas or regenerate into specialized cells to replace the ones that are dead or damaged.
The third type of stem cells, which are genetically reprogrammed in the laboratory, are induced pluripotent stem cells. After years of stem cell research and development, it was discovered that artificially triggering certain genetic components would prompt different cells to become pluripotent stem cells, which were similar in nature to embryonic stem cells. This helps avoid ethical concerns associated with using human embryonic tissue for research and regenerative medicine.
The following video from an Arizona pain doctor goes into detail about how stem cell therapy for pain works.
There are twomajor types of stem cells: those harvested from adults and those harvested from embryonic tissues.
However, there are other ways to retrieve stem cells that reduce the use of embryonic stem cells, including:
As the Euro Stem Cell organization reports, some of these types of stem cells are more effective than others.
One source of stem cells is human embryos. These cells are called pluripotent stem cells, and theyre very useful to researchers because they can be multiplied indefinitely in the laboratory. Although these cells are often cultivated from embryos that are just a few days old, they can also be taken from fetal tissue thats older than eight weeks, according to the National Institutes of Health (NIH).
The majority of therapeutic stem cells come from adults. Even though embryos are the richest source of stem cells, humans of all ages have stem cells. Stem cells give adults the ability to replace damaged tissue, heal wounds, and grow hair.The patients own adult stem cells are extracted, purified, concentrated, and then injected into the damaged tissue. This process is usually non-surgical and the individual has very little recovery time. Most patients report only some soreness around the site of the injection. Sometimes there is also slight bruising. There have been no reports of serious side effects from treatments using stem cell therapy.
Newer research has given scientists the ability to reprogram specialized adult cells so they essentially return to their original stem cell state. These reprogrammed cells are known as induced pluripotent stem cells. Although this ability exists, scientists arent sure how or if these artificially created stem cells behave differently than other types.
Despite these unknowns, the reprogrammed stem cells are already being used in the development of medicines and helping scientists learn more about specific types of diseases, according to NIH.
Stem cells have many uses, and the full spectrum of their application isnt yet known. One way stem cells are helping researchers is by illuminating the inner workings of various diseases. Stem cells offer scientists the ability to model human disease progression in a laboratory setting.
This is exciting because many studies rely on animals with similar, but not exact, biology to humans. The more scientists can understand about human-specific disease progression, the greater insight they have regarding potential treatments.
For example, one of the earliest uses for stem cells were bone marrow transplants, used to help patients with leukemia or sickle cell anemia heal. This treatment has been used for more than 40 years. In addition, stem cell therapy may be used to treat:
The application of most interest to chronicpatients is likely the emerging field of regenerative medicine, which is the science of helping tissues regenerate. This field examines the potential of stem cells to repair damaged tissue and heal areas of the body bone and potentially organs, too affected by arthritis, diabetes, spinal cord injuries, nerve damage, Parkinsons disease, and more.
Exciting research has also uncovered the potential for stem cells to expand the number of lungs available for transplant. A portion of lungs available for transplant arent used because they become damaged. However, research from the American Physiological Society has found stem cells could help repair the organs and prepare them to save lives.
Other recent researchstories include:
For many of the studies underway, time is needed to fully examine the benefits and potential dangers of this treatment. Another obstacle is obtaining specific types of adult stem cells. Theyre difficult to grow in the laboratory, making it hard to produce the large numbers available for research.
Another potential issue with donor stem cells is the possibility of rejection. The immune system of the recipient could reject the cells, essentially making it difficult for the treatment to work as intended and causing ancillary problems.
Finally, since this is such a new treatment area, some government agencies are calling for more oversight of its use. Others are pushing back, claiming that stem cell therapy provides a new area of treatment for patients who have exhausted all other options.
That being said, even though there are complications and roadblocks to its use, the benefits of stem cell therapy could be huge. As the American Academy of Anti-Aging Medicine notes:
[A]n analysis of the potential benefits of stem cells based therapies indicates that 128 million people in the United States alone may benefit with the largest impact on patients with Cardiovascular disorders (5.5 million), autoimmune disorders (35 million) and diabetes (16 million US patients and more than 217 million worldwide).
Californias Stem Cell Agency gives a great overview of this process, noting:
In order to be approved by the FDA for use in human trials, stem cells must be grown in good manufacturing practice (GMP) conditions. Under GMP standards, a cell line has to be manufactured so that each group of cells is grown in an identical, repeatable, sterile environment. This ensures that each batch of cells has the same properties, and each person getting a stem cell therapy gets an equivalent treatment. Although the FDA hasnt yet issued guidelines for how pluripotent stem cells need to meet GMP standards, achieving this level of consistency could mean knowing the exact identity and quantity of every component involved in growing the cells.
Stem cell therapy is being studied for a number of chronic pain conditions, especiallypain in the:
Stem cell therapy for pain could help reduce the inflammation that results in chronic pain, or it could help to heal regenerative conditions that lead to pain, such as arthritis.
Using stem cell therapy for knee pain is one of the leading areas of research. Stem cell therapy for knees can be provided as stem cell injections or as blood platelet treatments from the body itself (another form of regenerative medicine).These two treatments may help relieve pain associated with:
The leading researchers on stem cell therapy for knee pain claim that it can help patients avoid surgery, with its associated costs and risks.
Since stem cell therapy promises to treat a number of conditions related to degenerative conditions, like arthritis and tendonitis, stem cell therapy may present a great treat option for hip pain related to these causes.
The National Multiple Sclerosis Society is leading the efforts in research, but currently reports the following:
At present, there are no approved stem cell therapies for MS. Larger, longer-term, controlled studies are needed to determine the safety and effectiveness of using stem cells to treat MS. When the results of these and subsequent clinical trials are available, it should be possible to determine what the optimal cells, delivery methods, safety and actual effectiveness of these current experimental therapies might be for different people with MS.
Potentially. One of our sister clinics, Arizona Pain, is participating in a study evaluating the potential of stem cells to reduce back pain related to degenerative disc disease. This progressive condition sometimes results from injury, but other times has no clear cause.
The study is exciting because it involves stem cells harvested from the bone marrow of healthy, young adults, and therefore itdoesnt come with the ethical concerns of embryonic stem cells. So far, the results have been very positive, and a significant number of people who received stem cells for their back pain have experienced reduced discomfort and improved quality of life.
This study is currently in Phase III, which is the phase immediately preceding potential FDA approval. This means it could soon be available to many more patients and potentially covered by insurance, although each insurance companys coverage policy varies.
Absolutely, and the research into this area is very promising. In fact, scientists have recently uncovered the specific type of stem cell most likely to reduce arthritis pain. Theyre special cells that are specifically able to rebuild tissue, bone, and cartilage, potentially offering much relief to osteoarthritis patients.
What other questions do you have regarding stem cell therapy for pain? If youre ready to learn more about using stem cell therapy to treatyour pain, click the button below to find a pain specialist in your area.
See original here:
15 Stem Cell Therapy For Pain Questions, Answered
- Stem Cell Therapy: Alternative Treatment to Hip & Knee ... - November 22nd, 2021
- How The Overlap Between Artificial Intelligence And Stem Cell Research Is Producing Exciting Results - Forbes - November 22nd, 2021
- Selma Blair Posts Nude Diving Photo After MS Stem Cell ... - November 22nd, 2021
- Stem Cell Therapy Reduces Need for Nearly 10% of Hip Replacements - Yale School of Medicine - November 22nd, 2021
- Stem cell therapy for heart failure lowers risk of adverse outcomes - Cardiovascular Business - November 22nd, 2021
- A second HIV patient may have been 'cured' of infection without stem cell treatment, in extremely rare case - CNN - November 22nd, 2021
- The Promise of Stem Cells to Help Children with Autism - Entrepreneur - November 22nd, 2021
- Global Cell Therapy Manufacturing Market Competition Forecast & Opportunities to 2026 - ResearchAndMarkets.com - Galveston County Daily News - November 22nd, 2021
- Dr Pengyi Yang wins National Stem Cell Foundation Metcalf Prize - News - The University of Sydney - November 22nd, 2021
- BioRestorative Therapies Enters into Letter of Intent with PRC Clinical - BioSpace - November 22nd, 2021
- SC21- 21st century cellular medicines specialists - The Thaiger - November 22nd, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- New hope for bowel cancer patients as fresh partnership between Carina Biotech and CellVec enables advancement of clinical trials. - Bio-IT World - November 22nd, 2021
- FDA Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Business... - November 22nd, 2021
- Mum with brain fog and pins and needles in hands devastated by 'ticking time bomb' MS - Mirror.co.uk - November 22nd, 2021
- CAR T-cell therapy: Hear from a Canadian patient - CTV News - November 8th, 2021
- Talaris therapy ends need for immune drugs in transplant patients - - pharmaphorum - November 8th, 2021
- Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL - OncLive - November 8th, 2021
- Parkinson's gene therapy restores responses to dopamine-boosting drug in mouse models - FierceBiotech - November 8th, 2021
- Studies: CAR-T therapies superior to standard treatment in blood cancer - STAT - November 8th, 2021
- Salit Discusses the Use of Staging and Grading for Patients With GVHD to Choose Appropriate Treatment - Targeted Oncology - November 8th, 2021
- Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates - BioSpace - November 8th, 2021
- Global Stem Cell Therapy Market Size, Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2026 - Northwest Diamond Notes - November 8th, 2021
- BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting &... - November 8th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - Yahoo Finance - November 8th, 2021
- Bacterial Infections Linked with Unapproved Stem Cell Treatments - Contagionlive.com - October 28th, 2021
- Team finds way to enhance stem cell therapy for CNS injuries - BioPharma-Reporter.com - October 28th, 2021
- Stem cell therapy can help combat common symptoms of aging - The Mountaineer - October 28th, 2021
- Stem Cells Used to Treat Avascular Necrosis of the Femoral Head - Yale School of Medicine - October 28th, 2021
- Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel... - October 28th, 2021
- Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM (Antibody Recruiting Molecule) Platform, in Combination with NK Cell... - October 28th, 2021
- The Power of the Immune System: New Treatment for Painful Blood Cancer Side Effect - Curetoday.com - October 28th, 2021
- Global Cell Therapy Market Research Report 2021: Opportunities with the Approval of Kymriah and Yescarta Across Various Countries -... - October 28th, 2021
- Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell Lymphoma - Targeted Oncology - October 28th, 2021
- Stem Cell Therapy Market Research Report by Cell Source, by Type, by Therapeutic Application, by End-User, by Region - Global Forecast to 2026 -... - October 16th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 16th, 2021
- A New Line of Defense in Blood Cancer: Natural Killer Cell Therapy - Curetoday.com - October 16th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 16th, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market By Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells) and By... - October 16th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress - Yahoo Finance - October 16th, 2021
- Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft - MedCity News - October 16th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 16th, 2021
- Newer Agents for DLBCL Show Potential for Earlier Use in the Course of Treatment - Targeted Oncology - October 16th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 16th, 2021
- Worldwide Cell Therapy Consumables Industry to 2031 - Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others - PRNewswire - October 16th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 16th, 2021
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 16th, 2021
- FTC Follows Through On Prioritizing Investigations Into False Advertising In Healthcare Markets - Media, Telecoms, IT, Entertainment - United States -... - October 16th, 2021
- Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why Its So Aggressive - On Cancer - Memorial Sloan Kettering - October 16th, 2021
- Actress Jennifer Garner Visits with 7-Year-Old Girl Fighting B-cell Acute Lymphoblastic Leukemia; What is the Treatment for This Disease? -... - October 16th, 2021
- Four-year-old girl with stage four cancer trying to get to America for clinical trial - Lancashire Telegraph - October 16th, 2021
- Stem cell & gene therapy to treat osteogenesis imperfecta: hype or hope - Open Access Government - October 5th, 2021
- Chennai-based institute to begin clinical trial on stem cell therapy for liver disease - The New Indian Express - October 5th, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 5th, 2021
- Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal - October 5th, 2021
- Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment - Yahoo Finance - October 5th, 2021
- Ready to Treat Over 80 Life-Threatening Diseases, Discover the Potential of Cord Blood during World Cord Blood Day 2021 - PRNewswire - October 5th, 2021
- Transforming Growth Factor Sales Gaining Traction & to reach US$ 709.9 Mn with Significant Development in Cell Therapy Research - PRNewswire - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WITN - October 5th, 2021
- Brazil investigates the use of stem cells in the treatment of covid-19 The Clare People - The Clare People - October 5th, 2021
- Indianapolis mother gives 13-year-old son with sickle cell disease a 2nd chance at life - WTHR - October 5th, 2021
- US FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | DNA RNA and... - October 5th, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 5th, 2021
- 'Survivor' winner Ethan Zohn opens up about his cancer battle: I was a healthy, young guy. You never expect it to be you. - Yahoo Life - October 5th, 2021
- The Best Skincare Treatments For Time-Crunched Moms (Or Anyone Else Who Only Has Five Minutes To Spare) - Forbes - October 5th, 2021
- [PDF] Stem Cell Therapy Market Size Strong Revenue and Generated Opportunities UNLV The Rebel Yell - UNLV The Rebel Yell - August 31st, 2021
- Mike Tysons weird stem cell treatment has helped transform incredible body at 55 - Daily Star - August 31st, 2021
- Acute Monocytic Leukemia: Causes, Symptoms, and Treatment - Healthline - August 31st, 2021
- UC Davis and the School of Medicine set new records in research funding - UC Davis Health - August 31st, 2021
- NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network - August 31st, 2021
- DHEC Supports Awareness and Education during National Sickle Cell Awareness Month - SCDHEC - August 31st, 2021
- The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation - DocWire News - August 31st, 2021
- Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking... - August 31st, 2021
- Operational Highlights and Financial Results for the Year Ended June 30, 2021 - GlobeNewswire - August 31st, 2021
- Event to benefit 2 families with kids fighting cancer - Youngstown Vindicator - August 31st, 2021
- Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market - GlobeNewswire - August 31st, 2021
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... - August 31st, 2021
- Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01) -... - August 31st, 2021
- 2021 Pipeline Insight Report on Myocardial Infarction - Featuring AstraZeneca, Mesoblast and Boehringer Ingelheim Among Others -... - August 31st, 2021
- Mini brains grown in the lab sprout primitive eyes - Freethink - August 31st, 2021